NEW YORK – In cell and gene therapies, the genetic machinery is key to producing the proteins missing or dysregulated in a disease, but whether the therapeutic cassette reaches target cells and how ...

The Global Cell And Gene Therapy Market is valued at USD 20.5 Billion in 2024 and is projected to reach a value of USD 128.8 ...

Hathway’s technology uses natural epigenetic processes to dial gene activity up or down, rather than rewriting the genetic ...

PHILADELPHIA, PA — Interius BioTherapeutics has announced its participation in three key scientific gatherings this spring, ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...

Revvity serves the pharmaceutical and biotech industries, diagnostic labs, academia. and governments in more than 160 ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

CPTx GmbH, a pioneer in the therapeutic development and manufacturing of novel medicines built with single-stranded DNA, has ...

Gene therapy, the idea of fixing faulty genes ... called DFNA50 caused by mutations in microRNA, by using a novel in vivo CRISPR genome editing ... Researchers Discover Potential Mole Reversal ...

CPTx GmbH ("CPTx"), a pioneer in the therapeutic development and manufacturing of novel medicines built with single-stranded ...